AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Futura Medical PLC (LSE:FUM) CEO James Barder recently discussed the company's latest financial performance and future outlook with Proactive's Stephen Gunnion. Barder highlighted that Futura Medical has raised its guidance for both profit and revenue for the remainder of the year, following a significant increase in revenue. The company’s flagship product, Eroxon, a clinically proven treatment for erectile dysfunction, has now been launched in ten countries, with its latest market entry in Mexico.
Barder underscored the importance of Eroxon's upcoming launch in the U.S. market, where it will become the first over-the-counter (OTC) treatment for erectile dysfunction, distinguishing itself from competitors such as Viagra and Cialis, which still require prescriptions. This entry into the U.S. market represents a strategic milestone for the company.
The CEO also detailed Futura Medical’s strategy for sustainable growth and a robust product pipeline, with plans for future regional expansions. This strategy is supported by the company’s successful track record, including its achievement of generating its first profit. Revenue for the period increased by over 300%, reaching £7 million.
With a strong research and development team and ongoing expansion initiatives, Barder expressed confidence in Futura Medical's potential for continued growth. The company is focused on establishing a viable presence in the consumer healthcare sector, leveraging its innovative products and strategic market entries to drive future success.
